Clinical Trials Logo

Filter by:
  • Not yet recruiting  
  • Page [1] ·  Next »
NCT ID: NCT06469385 Not yet recruiting - Atopic Dermatitis Clinical Trials

Topical ENS-002 for Atopic Dermatitis in Adults

EnSync
Start date: July 10, 2024
Phase: Phase 1
Study type: Interventional

The goal of this study is to determine the safety and effects of ENS-002, a live biotherapeutic product (LBP) consisting of 3 distinct commensal, clonal, non-pathogenic bacteria in participants with atopic dermatitis.

NCT ID: NCT06469307 Not yet recruiting - Leukemia Clinical Trials

Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

DIVERSE
Start date: November 2024
Phase:
Study type: Observational

The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.

NCT ID: NCT06469281 Not yet recruiting - Clinical trials for Fallopian Tube Cancer

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Start date: June 28, 2024
Phase: Phase 1
Study type: Interventional

This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. This study has two (2) major parts: Phase 1a Dose Escalation and Phase 1b Dose Expansion. The aim of the dose escalation part will be to test the safety of 27T51 in a small number of participants to find the highest dose given to humans without unacceptable side effects. The aim of the dose expansion part will be to test 27T51 at the established dose level(s) from the dose escalation part and may include other medications given in combination with 27T51. Information collected from this study will help researchers understand more fully whether this immune cell therapy, also known as CAR T cell therapy, can be safely used to treat solid tumors such as ovarian cancer.

NCT ID: NCT06469242 Not yet recruiting - Presbyopia Clinical Trials

Clinical Performance of Two Frequent Replacement Silicone Hydrogel Multifocal Contact Lenses

Start date: July 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the on-eye multifocal clinical performance of investigational LID233309 contact lenses and Oasys multifocal (MF) contact lenses in a daily wear dispensing trial.

NCT ID: NCT06469164 Not yet recruiting - Bacterial Vaginosis Clinical Trials

A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis

Start date: July 2024
Phase: Phase 1
Study type: Interventional

This is a two-part, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy (for Part B) of BNT331 in healthy women (Part A) and in women diagnosed with bacterial vaginosis (BV) (Part B).

NCT ID: NCT06469151 Not yet recruiting - Clinical trials for Healthy Participants

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults

Start date: June 24, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to measure safety, tolerability, and pharmacokinetics (PK) of a single dose of AZD5148 administered via intravenous (IV) bolus or intramuscular (IM) injection in healthy participants.

NCT ID: NCT06468618 Not yet recruiting - Sleep Disturbance Clinical Trials

Developing Restful Environments and Management Strategies for Pediatric Stem Cell Transplant Patients

DREAMS
Start date: August 2024
Phase: N/A
Study type: Interventional

Pediatric patients undergoing stem cell transplant (SCT) are hospitalized for extended periods and are at high risk for sleep disturbances. In order to begin to address the environmental issues that SCT recipients face during inpatient hospitalizations, investigators will conduct a single arm pilot study of a program entitled 'Developing Restful Environments and Management Strategies' (DREAMS). The program will provide children receiving SCT and families with information and a kit that includes tools which may support sleep and circadian health during an inpatient hospitalization.

NCT ID: NCT06468202 Not yet recruiting - Preeclampsia Clinical Trials

Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

ASPIRIN
Start date: December 1, 2024
Phase: Phase 4
Study type: Interventional

The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits.

NCT ID: NCT06467708 Not yet recruiting - Clinical trials for TBI (Traumatic Brain Injury)

Transcutaneous Auricular Neurostimulation for ICU Patients With Traumatic Brain Injury

tAN-TBI
Start date: July 2024
Phase: N/A
Study type: Interventional

The overarching goal of this pilot study is to assess the feasibility and safety of transcutaneous auricular neurostimulation (tan) in ICU patients with TBi and to determine the effect of tan on serum markers of inflammation. exploratory analyses will examine effects on such physiological parameters as blood pressure, heart rate, and intracranial pressure (iCP), as well as measures of neurological function.

NCT ID: NCT06467487 Not yet recruiting - Clinical trials for Patient Participation

Electronic Health Record Strategies to Promote Diverse Participation in Research AIM 2

Start date: June 2024
Phase: N/A
Study type: Interventional

Based on the outcomes of the initial study (NCT05348603), this optimization study will employ the most effective interventions (letters and messages) and distribute these communications to underrepresented minorities to further promote interest in research. Optimized language will be distributed in English, Spanish, Portuguese, Chinese, Arabic, or Haitian Creole, based on preferred language identified in the patient profile in an electronic medical records system.